SUNDAY, SEPTEMBER 25, 2016

Delivery technology to improve vaccines for dengue fever

Particles of the dengue fever virus. | Courtesy of the CDC

A new program seeks to demonstrate how computational drug delivery technology can improve the vaccines used to protect people from contracting dengue fever from infected mosquitoes.

The dengue fever rate has increased significantly during the last 50 years. As of today, approximately 100 million people are infected with the disease each year.

The program, which is part of a contract awarded to Qrono from the U.S. Army Small Business Innovation Research (SBIR) Program, is one of the first steps to creating a vaccine that could rapidly induce lasting, complete protection against the fever. This would be the first vaccine of its kind.

Researchers intend to use the $150,000 SBIR Phase I opportunity to create a novel adjuvant design with computational methods.

“This effort takes the initial steps toward developing the world’s first vaccine capable of rapidly generating complete, lasting protection from dengue fever and will establish a new state-of-the-art in adjuvant design by using computational methods,” Qrono CEO Larry Zana said. “This vaccine promises not only to reduce the global economic impact of dengue but also to considerably reduce the worldwide human suffering and death it causes. Success of this new vaccine will establish M2 as a key adjuvant platform for use in vaccines for other pathogens such as influenza or Ebola.”

Organizations in this story

Qrono ,

Get notified the next time we write about Qrono!